SequelSEC

CHAMPIONS ONCOLOGY, INC. CSBR

Biological Products, (No Diagnostic Substances) · CIK 0000771856 · Fiscal year ends 0430

Revenue
$59.42M
Fiscal year ended 2026-04-30
Operating income
-$1.14M
Fiscal year ended 2026-04-30
Free cash flow
-$5.04M
Fiscal year ended 2026-04-30

CHAMPIONS ONCOLOGY, INC. (CSBR) reported revenue of $59.42M and net income of -$1.18M for the fiscal year ended 2026-04-30. This page shows 9 annual periods of income statement, balance sheet and cash flow figures normalized from CHAMPIONS ONCOLOGY, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

CHAMPIONS ONCOLOGY, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-30
Revenue$59.42M$56.94M$50.16M$53.87M$49.11M$41.04M$32.12M$2.90M$20.24M
Cost of revenue$30.90M$28.39M$29.40M$29.53M$23.63M$21.45M$17.00MUnavailableUnavailable
Gross profit$28.52M$28.56M$20.75M$24.34M$25.48M$19.59M$15.12MUnavailableUnavailable
Operating income-$1.14M$4.55M-$7.36M-$5.26M$607.00K$366.00K-$1.92M$270.00K-$1.35M
Net income-$1.18M$4.70M-$7.28M-$5.34M$548.00K$362.00K-$2.09M$128.00K-$1.48M
Research & development$9.08M$6.82M$9.54M$11.54M$9.37M$7.20M$5.85M$4.80M$4.40M
Weighted-average diluted sharesshares 13.83Mshares 14.27Mshares 13.55Mshares 13.54Mshares 14.16Mshares 14.57Mshares 11.84Mshares 14.10Mshares 10.99M
Pretax income-$929.00K$4.63M-$7.31M-$5.27M$583.00K$437.00K-$1.96M$231.00K-$1.44M
Income tax expense$246.00K-$75.00K-$32.00K$68.00K$35.00K$75.00K$130.00K$103.00K$33.00K
Diluted EPS$-0.08$0.33$-0.54$-0.39$0.04$0.02$-0.18$0.01$-0.13
Selling, general & administrative$20.47M$16.88M$18.13M$17.24M$15.50M$12.03M$10.86M$7.73M$6.64M
General & administrative$11.15M$9.34M$11.07M$10.24M$9.12M$6.51M$6.61M$4.68M$4.07M
Selling & marketing$9.32M$7.54M$7.06M$7.00M$6.38M$5.52M$4.24M$3.06M$2.57M

Balance

CHAMPIONS ONCOLOGY, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-30
Cash & equivalents$4.87M$9.78M$2.62M$10.12M$9.01M$4.69M$8.34M$3.24M$856.00K
Total assets$26.99M$32.34M$26.13M$34.31M$35.38M$27.59M$20.75M$11.26M$8.08M
Current assets$19.22M$22.36M$13.64M$19.46M$19.66M$12.63M$13.50M$7.92M$5.06M
Total liabilities$22.92M$28.57M$28.04M$29.68M$26.28M$20.16M$15.65M$9.03M$8.08M
Current liabilities$19.92M$23.85M$21.54M$21.73M$17.48M$11.20M$12.30M$8.02M$7.45M
Total equity incl. NCI$4.07M$3.77M-$1.90M$4.64M$9.10M$7.43M$5.10M$2.14M$3.00K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$13.18M$11.20M$9.53M$8.01M$9.51M$6.99M$4.77M$4.38M$3.92M
Goodwill$335.00K$335.00K$335.00K$335.00K$335.00K$335.00K$335.00K$669.00K$669.00K
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$6.90M$4.25M$5.80M$5.33M$2.87M$1.89M$3.14M$2.81M$2.15M

Cash flow

CHAMPIONS ONCOLOGY, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-30
Operating cash flow-$4.47M$7.39M-$6.14M$3.97M$6.50M-$1.68M$2.90M$1.86M-$1.23M
Capital expenditures$564.00K$389.00K$836.00K$2.87M$2.38M$3.28M$2.22M$834.00K$1.23M
Investing cash flow-$540.00K-$389.00K-$836.00K-$2.87M-$2.38M-$3.17M-$2.22M-$834.00K-$1.23M
Financing cash flow$99.00K$170.00K-$527.00K$11.00K$207.00K$1.20M$4.42M$1.20M$13.00K
Net change in cash-$4.91M$7.17M-$7.50M$1.11M$4.32M-$3.66M$5.10M$2.23M-$2.44M
Stock-based compensation$1.24M$654.00K$1.12M$864.00K$912.00K$598.00K$600.00K$636.00K$1.00M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailable$0$634.00K$74.00K$0UnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.40M$1.60M$1.90M$2.10M$1.50M$925.00K$825.00K$606.00K$360.00K

Derived

CHAMPIONS ONCOLOGY, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-04-302025-04-302024-04-302023-04-302022-04-302021-04-302020-04-302019-04-302018-04-30
Free cash flow-$5.04M$7.00M-$6.97M$1.10M$4.11M-$4.96M$685.00K$1.03M-$2.46M
Gross margin48.0%50.1%41.4%45.2%51.9%47.7%47.1%UnavailableUnavailable
Operating margin-1.9%8.0%-14.7%-9.8%1.2%0.9%-6.0%9.3%-6.7%
FCF margin-8.5%12.3%-13.9%2.0%8.4%-12.1%2.1%35.4%-12.1%
SBC / revenue2.1%1.1%2.2%1.6%1.9%1.5%1.9%21.9%5.0%
Current ratio0.96x0.94x0.63x0.90x1.13x1.13x1.10x0.99x0.68x
Revenue YoY growth4.4%13.5%-6.9%9.7%19.7%27.8%1007.7%-85.7%Unavailable
Net margin-2.0%8.3%-14.5%-9.9%1.1%0.9%-6.5%4.4%-7.3%
R&D / revenue15.3%12.0%19.0%21.4%19.1%17.5%18.2%165.4%21.7%
CapEx / revenue0.9%0.7%1.7%5.3%4.9%8.0%6.9%28.8%6.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable-1.6%UnavailableUnavailable6.0%17.2%Unavailable44.6%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CSBR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-09-11View SEC filing
10-K · Filed 2026-07-27View SEC filing
10-Q · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-12-15View SEC filing
10-Q · Filed 2025-09-15View SEC filing
10-K · Filed 2025-07-23View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.